arrow
H

Hiroki Izumi

National Cancer Center Hospital East
H指数:21
被引数:1,900

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dysregulation of the Hippo pathway enhances PD-L2 transcription to promote immune evasion in head and neck squamous cell carcinoma

Hippo通路失调增强PD-L2转录以促进头颈鳞状细胞癌的免疫逃逸

2026-10-230
OAAI
Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)

EGFR酪氨酸激酶抑制剂在携带EGFR外显子19插入突变的非小细胞肺癌患者中的疗效:基于LC-SCRUM-Asia(多机构基因组筛查登记)的临床-基因组学及体外研究分析

2025-04-010
OAAI
Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma

肿瘤相关成纤维细胞中实性占优势的组织学和podotlanin的高表达可预测EGFR突变的肺腺癌对奥希替尼的原发性耐药

2025-03-011
OA
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer
CANCER
IF5.1
2025-01-280
OAAI
Genomic profiling for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-advantage/MRD

早期非小细胞肺癌患者围手术期靶向治疗的基因组分析:LC-SCRUM-advantage/MRD

2024-12-010
PRE
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer
2024-11-120
OAAI
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
2024-01-297
OAAI
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Tarlatamab用于先前治疗的小细胞肺癌患者

2023-11-3091
PRE
Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-smallcell lung cancer (NSCLC): ARTEMIDE-01
2023-10-010
PRE